ClinicalTrials.gg
CompletedNCT07944807Updated Nov 18, 2026

Ligasure Hemorrhoidectomy Short Term Follow Up

An interventional study of LigaSure Hemorrhoidectomy and Conventional Hemorrhoidectomy in LigaSure Hemorrhoidectomy, Conventional Hemorrhoidectomy and Hemorrhoids, sponsored by Sohag University. Completed at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Sohag University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled May 2025, registered Nov 2026).
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 12 studies in Hemorrhoids with a site in Egypt — 6 open to participants now, 6 under way, none of them phase 3. Hemorrhoids · Egypt.

Enrollment
6th of 12
90 · median 90
Started
2025
with 1 other
No phase
12 of 12
6 open now
Registered
12th of 12
by date
Lead sponsor
3 of 12
Sohag University

Among the 12 studies in Hemorrhoids with a site in Egypt, this one is the 6th largest by enrollment, is one of 2 that started in 2025, is one of 12 with no phase, and was the 12th registered.

Hemorrhoids

240 studies on the registry are indexed under Hemorrhoids; 73 are open to participants now.

Browse Hemorrhoids studies →

Open to participants now

6 of the 12 studies in Hemorrhoids with a site in Egypt are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 38 Hemorrhoids studies recruiting now, 15 (39%) set no upper age limit and 11 (29%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hemorrhoids with a site in Egypt, or all of them as a file.
02

Study summary

This study aimed to compare the short-term outcomes of LigaSure hemorrhoidectomy and conventional diathermy hemorrhoidectomy.

Read the detailed description

Hemorrhoidal disease affects about 5% of the general population. Excisional hemorrhoidectomy remains the definitive treatment for individuals with grade III and IV hemorrhoids.

Several clinical trials have assessed LigaSure hemorrhoidectomy [LH] with conventional excisional techniques. A pooled analysis of previous trials described better short-term results with LH, including shorter operating time, less intraoperative blood loss, less pain after surgery scores, an earlier return to normal activity, and faster wound healing.

Despite these encouraging results, delayed postoperative bleeding after LH still warrants attention. One comparison of LH with Ferguson [closed] hemorrhoidectomy found similar rates in postoperative bleeding between the two techniques.

03

Conditions studied

  • LigaSure Hemorrhoidectomy
  • Conventional Hemorrhoidectomy
  • Hemorrhoids
  • Postoperative Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 years.
  • Both sexes.
  • Patients who needed surgery for symptomatic grade III or IV hemorrhoids.

Exclusion criteria

Exclusion Criteria:

  • Patients underwent prior anal or anorectal operation.
  • Anal fissure.
  • Fistula or abscess.
  • Thrombosed hemorrhoids.
  • Anal incontinence.
  • Pregnancy.
  • Liver cirrhosis.
  • Poorly controlled diabetes mellitus.
  • Inflammatory bowel disease.
  • Colorectal cancer.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    LigaSure Hemorrhoidectomy Group

    Participants underwent excisional hemorrhoidectomy with the LigaSure vessel sealing system.

    Procedure: LigaSure Hemorrhoidectomy

  • Experimental
    Conventional Hemorrhoidectomy Group

    Participants underwent conventional open diathermy hemorrhoidectomy with the Milligan-Morgan technique.

    Procedure: Conventional Hemorrhoidectomy

Interventions

  • ProcedureLigaSure Hemorrhoidectomy

    Participants underwent excisional hemorrhoidectomy with the LigaSure vessel sealing system.

  • ProcedureConventional Hemorrhoidectomy

    Participants underwent conventional open diathermy hemorrhoidectomy with the Milligan-Morgan technique.

06

What researchers measure

Primary outcomes

  1. Degree of pain

    Postoperative pain intensity was assessed using the visual analog scale (VAS). VAS range from 0 (no pain) to 10 (worst imaginable pain).

    Time frame: 24 hours after surgery

Secondary outcomes

  1. Operative duration

    Operative duration was recorded from the start of surgery till the end of surgery.

    Time frame: Till the end of surgery (Up to 2 hours)

  2. Length of Hospital Stay

    Length of Hospital Stay was recorded from the admission till the discharge from hospital.

    Time frame: Till the discharge from hospital (Up to 2 weeks)

  3. Time to Return to Work

    Number of days from surgery until the participant resumes work.

    Time frame: 6 months postoperatively

  4. Incidence of postoperative complications

    Incidence of postoperative complications were recorded.

    Time frame: 6 months postoperatively

  5. Degree of patient satisfaction

    Degree of patient satisfaction was assessed on a 5-point Likert scale patient satisfaction (1, extremely dissatisfied; 2, unsatisfied; 3, neutral; 4, satisfied; 5, extremely satisfied)

    Time frame: 24 hours after surgery

07

Study locations

1 site
  • Sohag University
    Sohag, 82511, Egypt
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

Time frame: After the end of study for one year.

Access criteria: The data will be available upon a reasonable request from the corresponding author.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Apr 2026, 11 months.

Of 67 non-industry interventional studies with no phase under Hemorrhoids, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's 11 months is below that.

Counting every sponsor, half of 72 studies reached it within 20 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartActual
May 1, 2025
Primary completionActual
Apr 1, 2026
CompletionActual
Apr 1, 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944807
Lead sponsor
Sohag University
Responsible party
Ahmed Rafaat Saad (Lecturer of General Surgery and Laparoscopic Surgery and Surgical Oncology, Faculty of Medicine, Sohag University, Sohag, Egypt., Sohag University) — Principal investigator
First posted
Nov 18, 2026
Start date
May 1, 2025
Primary completion
Apr 1, 2026
Completion
Apr 1, 2026
Last update
Nov 18, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion